IMMX News and Press, Immix Biopharma Inc. From 05/20/22

Immix Biopharma (NASDAQ:IMMX) on Friday announced positive data from animal study trial to test its lead candidate, IMX-110, ti treat Soft Tissue Sarcoma (STS). (IMMX) surged 60% before the bell. The study showed that after one cycle of treatment the drug produced 75% surv...

One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs ...

Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...

Immix Biopharma (NASDAQ:IMMX) said it has received Board's approval on Monday to repurchase up to $1M of its common shares. As of Apr. 15, 2022, the company had about 13.9M shares outstanding. "We are confident that with the $24.2 million gross proceeds raised in our recent IPO, ImmixBio is s...

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-d...

Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...

Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...

The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDay Management discussed financial position, milestones, and new opportunities presented by current market volatility ImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022...

Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcem...

IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The inflammatory bowel disease market is expected to reach $21.4 billion by 2...